Curevo to be Acquired by Lilly to Advance Next-Generation Shingles PreventionCurevo’s lead asset, amezosvatein, is a Phase 3-ready shingles vaccine with potential to increase vaccination rates by delivering improved tolerability versus approved products
Curevo Enrolls First Participants in Phase 2 Extension TrialTrial targets enrollment of 640 participants aged 50 and over to receive amezosvatein or Shingrix®
Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine-- Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study
Curevo Announces Positive Updated Phase 2 Data for Amezosvatein Shingles Vaccine-- One year after the second vaccine dose, the anti-gE antibody immune response to amezosvatein continues to be non-inferior to Shingrix
Curevo Vaccine to present at the 43rd Annual J.P. Morgan Healthcare ConferenceSEATTLE, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced it has been selected to present in the Private Company Track at the 43rd Annual J.P. Morgan Healthcare Conference.
Curevo Presents Positive Shingles Vaccine Outcomes Data-- Zero shingles cases after 18.8 months follow-up in 619 patients receiving any dose of amezosvatein, a development-stage adjuvanted subunit vaccine
Curevo Vaccine Presents Amezosvatein Shingles Vaccine Data at ID Week-- Positive data from 876-patient head-to-head trial versus Shingrix® shows amezosvatein elicits robust humoral and cellular immune responses with comparatively lower reactogenicity
Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory OfficerChi Li, PhD, MBA, RAC adds over 20 years of global regulatory experience and success to the Curevo Vaccine executive team
Curevo Vaccine Announces Positive Topline Results from Phase 2 Trial of Amezosvatein, a Next-Generation Vaccine for Shingles, Head-to-Head vs. Shingrix-- Positive data from 876-patient head-to-head trial versus Shingrix® shows amezosvatein met the primary immunogenicity endpoint, eliciting a robust immune response non-inferior to Shingrix, including a 100% vaccine response rate
Curevo Vaccine to present at the 42nd Annual J.P. Morgan Healthcare ConferenceSEATTLE, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced it has been selected to present in the Private Company Track at the 42nd Annual J.P. Morgan Healthcare Conference.
Guy De La Rosa, MD, Joins Curevo Vaccine as Chief Medical OfficerDr. De La Rosa adds over 20 years of big pharma and biotech infectious disease clinical trial experience to Curevo Vaccine
Curevo Vaccine Announces $26 Million Series A1 Financing to Support Clinical Development of Next-Generation Subunit Vaccines
Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced the closing of a $26 million Series A1 financing round.
Curevo Vaccine Announces $60 Million Series A Financing to Support Clinical Development of Next Generation Subunit Vaccines
Curevo Vaccine (Curevo), a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly-effective vaccines, today announced the closing of a $60 million Series A financing round.
